Osiris (OSIR) Q3/11 Results
Net income was $4M or $0.12 per diluted share
Net income for Q3/11 was $4M compared to $4.5M in Q3/10. Revenues were $10.6M in Q3/11, consisting primarily of the amortization of license fees from collaboration agreements. Gross profit was $192K. Cost of goods sold was $139K. Q3 R&D expenses were $5M, compared to $5.5M in Q3/10. G&A expenses were $1.4M for Q3/11 compared to $1.3M for Q3/10. Net cash used in operations was $4.4M. Weighted average common shares were 33.12M.
- Cash, receivables and short-term investments of $53.3M as of 9/30/11
Related Posts
Categories: Osiris Therapeutics, Q3/11 Results
